Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Administration of Autologous Mesenchymal Stem Cell Transplantation for Treatment of Type 1 Diabetes Mellitus



Nasli Esfahani E1 ; Ghavamzadeh A2 ; Mojahedyazdi N1 ; Hashemian S1 ; Alimoghadam K2 ; Aghel N3 ; Nikbin B4 ; Larijani B3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Hematology-Oncology & Stem Cell Transplantation Research Center, Shariati Hospital, Tehran university of Medical Sciences, Tehran, Iran
  3. 3. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Molecular Immunology Research Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Public Health Published:2015

Abstract

Background: The aim of the present clinical trial was to investigate the efficacy of autologous bone marrow mesen-chymal stem cells (BM-MSCs) in glycemic control of diabetic patients without using any immunosuppressive drugs over a nine-month period. Method: Twenty-three patients with T1DM, at 5 to 30 years of age and in both sexes, participated in this study. This trial consisted of two phases; in the end of the first phase (three month after the transplantation), if the patient still needed exogenous insulin to control his/her glycemic state, the second phase of study was performed. In both phases, 100 milliliter of mixed mesenchymal stem cells and normal saline containing 2×10⁶ autologous cells/kg for each patient was delivered to patients through cubital vein. All patients were evaluated at 1, 3, 6 and 9 months after the proce-dure. Result: Twenty-one patients underwent a second injection. Nine patients (39%) responded positively and 14 patients (61%) responded negatively based on their HbA1c levels and insulin requirements in both injections. Two patients became insulin-free during two rounds of injections. In responder patients, mean levels of C-peptide and HbA1c as well as prescribed insulin dosage significantly decreased compared to baseline measures (P=0.002, P=0.007 and P<0.001). In the second phase, responder patients did not show significant reduction in C-peptide levels compared to the baseline of the second phase. Mean levels of HbA1c and prescribed insulin dosage significantly decreased in comparison to the beginning of the study (P<0.05). Conclusion: Transplantation of BM-MSC can be viewed as a promising, simple, safe, and efficient therapeutic modal-ity for T1DM. © 2015, Tehran University of Medical Sciences. All rights reserved.
Other Related Docs
17. Multipotent Stem Cell and Current Application, Acta Medica Iranica (2017)
20. Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis, Current Stem Cell Research and Therapy (2016)
33. Menstrual Blood-Derived Stromal Stem Cells Augment Cd4+ T Cells Proliferation, Avicenna Journal of Medical Biotechnology (2018)
34. Stem Cell Tracing Through Mr Molecular Imaging, Tissue Engineering and Regenerative Medicine (2018)
36. Application of Fetal Stem Cells in Diabetes: Iran’S Experience, Iranian Journal of Public Health (2015)
38. Therapeutic Application of Multipotent Stem Cells, Journal of Cellular Physiology (2018)